# Sichuan Baili Pharmaceutical Co., Ltd. trials: 136 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 136 trials with Sichuan Baili Pharmaceutical Co., Ltd. as lead sponsor, 93 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Sichuan Baili Pharmaceutical Co., Ltd.: 136 rows for $6.80, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 136
- Recruiting or not yet: 93
- Read on: November 19, 2026

## Trials

The 25 newest of 136, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 25, 2026 | NCT07841925 | A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Melanoma, Solid Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841925) |
| September 23, 2026 | NCT07837622 | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Urothelial Carcinoma (UC), Solid Tumors | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837622) |
| September 18, 2026 | NCT07827261 | A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827261) |
| September 14, 2026 | NCT07818499 | A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818499) |
| September 14, 2026 | NCT07818486 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC), Solid Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818486) |
| September 1, 2026 | NCT07797881 | A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797881) |
| August 31, 2026 | NCT07793825 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Gynecological Tumors, Solid Tumors | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793825) |
| August 27, 2026 | NCT07788950 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Head and Neck Squamous Cell Carcinomas, Solid Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788950) |
| August 24, 2026 | NCT07783321 | A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC) | 404 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783321) |
| August 21, 2026 | NCT07780318 | A Study of BL-M08D in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Gastrointestinal Tumors, Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780318) |
| August 21, 2026 | NCT07778862 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gynecological Tumors and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Gynecological Tumors, Solid Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778862) |
| August 17, 2026 | NCT07769229 | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Gynecological Malignancies, Solid Tumors | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07769229) |
| August 13, 2026 | NCT07763652 | A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Gastrointestinal Tumors, Solid Tumors | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763652) |
| August 13, 2026 | NCT07763639 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Head and Neck Tumors, Solid Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763639) |
| August 7, 2026 | NCT07753226 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Breast Cancer, Solid Tumor | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753226) |
| August 4, 2026 | NCT07744243 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Urological Cancer, Solid Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744243) |
| July 31, 2026 | NCT07739199 | A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2/3 | Recruiting | Squamous Non-small-cell Lung Cancer | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739199) |
| July 31, 2026 | NCT07739186 | A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2/3 | Recruiting | Non-squamous Non-small Cell Lung Cancer | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739186) |
| July 28, 2026 | NCT07730489 | A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Colorectal Cancer | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730489) |
| July 28, 2026 | NCT07729956 | A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Triple-Negative Breast Cancer (TNBC) | 436 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729956) |
| July 1, 2026 | NCT07678970 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Gastrointestinal Tumor, Solid Tumor | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678970) |
| July 1, 2026 | NCT07678957 | A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Breast Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678957) |
| June 15, 2026 | NCT07648914 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Breast Cancer | 446 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648914) |
| June 11, 2026 | NCT07642024 | A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2/3 | Recruiting | Non-small Cell Lung Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642024) |
| June 11, 2026 | NCT07641855 | A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2/3 | Not yet recruiting | Castration-resistant Prostate Cancer | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641855) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 45 |
| Phase 1/2 | 19 |
| Phase 2 | 36 |
| Phase 2/3 | 8 |
| Phase 3 | 26 |
| Phase 4 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 77 |
| Active not recruiting | 38 |
| Not yet recruiting | 16 |
| Unknown | 2 |
| Withdrawn | 1 |
| Completed | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 21 |
| Breast Neoplasms | 13 |
| Squamous Cell Carcinoma of Head and Neck | 11 |
| Digestive System Neoplasms | 8 |
| Colorectal Neoplasms | 7 |
| Nasopharyngeal Carcinoma | 6 |
| Small Cell Lung Carcinoma | 5 |
| Carcinoma, Transitional Cell | 4 |
| Lymphoma, Non-Hodgkin | 4 |
| Triple Negative Breast Neoplasms | 4 |
| Hematologic Neoplasms | 4 |
| Esophageal Neoplasms | 4 |
| Recurrence | 3 |
| Leukemia, Myeloid, Acute | 3 |
| Uterine Cervical Neoplasms | 3 |
| Stomach Neoplasms | 3 |
| Carcinoma, Ovarian Epithelial | 2 |
| Fallopian Tube Neoplasms | 2 |
| Head and Neck Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Tachycardia, Ventricular | 2 |
| Ventricular Fibrillation | 2 |
| Urologic Neoplasms | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Esophageal Squamous Cell Carcinoma | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Indian restaurants in the United States](https://specstream.ai/data/businesses/indian-restaurants/united-states)
- [Appellate practice law firms in the United States](https://specstream.ai/data/businesses/appellate-practice-law-firms/united-states)
- [Lodges in the United States](https://specstream.ai/data/businesses/lodges/united-states)
- [Bakeries in the United States](https://specstream.ai/data/businesses/bakeries/united-states)
- [Occupational medicine clinics in the United States](https://specstream.ai/data/businesses/occupational-medicine-clinics/united-states)
